Novavax Inc ( NVAX ) shares are trading lower by 9.8% to $8.40 during Monday’s session amid weakness in vaccine stocks after Moderna issued 2025 revenue guidance below analyst estimates.

What To Know: Shares of several vaccine makers, including Novavax ( NVAX ), dropped sharply on Monday as Moderna’s announcement of lower-than-expected 2025 revenue projections rattled investor confidence across the sector.

Moderna, whose stock fell around 23% Monday morning, expects 2025 revenues of $1.5 billion to $2.5 billion, significantly below the consensus of $2.95 billion, largely tied to weakening demand for its Spikevax COVID-19 vaccine and mRESVIA RSV vaccine.

Read Also: Why Novavax Stock Is Volatile This Week

The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand continues to wane.

What Else: Novavax ( NVAX ), which relies heavily on its COVID-19 vaccine sales, saw its stock decline likely amid fears that heightened competition from Moderna's streamlined portfolio strategy could erode market share further.

The selloff could also reflect a broader skepticism about vaccine makers’ ability to adapt to post-pandemic market realities, with investors reevaluating growth prospects and long-term demand for new and existing products in the space.

Read Also: Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?

Should I Sell My NVAX Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Novavax ( NVAX ) have gained 94.47% year to date. This compares to the average annual return of -56.39%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Novavax ( NVAX ) stock currently has an RSI of 58.05, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.